NeOnc Technologies Files IPO Amendment
Ticker: NTHI · Form: S-1/A · Filed: Jan 31, 2025 · CIK: 1979414
Sentiment: neutral
Topics: ipo, sec-filing, pharmaceuticals
TL;DR
NeOnc IPO filing updated. Get ready.
AI Summary
NeOnc Technologies Holdings, Inc. filed an S-1/A amendment on January 30, 2025, for its initial public offering. The company, incorporated in Delaware, is in the Pharmaceutical Preparations sector and is headquartered at 2 Dole Drive, Westlake Village, CA. The filing details its registration statement under the Securities Act of 1933, with SEC file number 333-284115.
Why It Matters
This S-1/A filing provides updated information for investors considering an initial public offering, detailing the company's structure, registration, and key contact information.
Risk Assessment
Risk Level: medium — As an S-1/A filing, it indicates a company is in the process of going public, which inherently carries risks associated with market reception and financial projections.
Key Numbers
- 333-284115 — SEC File Number (Identifies the specific registration statement)
- 2834 — SIC Code (Indicates industry classification (Pharmaceutical Preparations))
Key Players & Entities
- NEONC TECHNOLOGIES HOLDINGS, INC. (company) — Registrant
- 0001829126-25-000575 (filing_id) — Accession Number
- 20250131 (date) — Filing Date
- 333-284115 (filing_number) — SEC File Number
- 2 Dole Drive Westlake Village, CA 91362 (address) — Principal Executive Offices
- Dr. Thomas C. Chen (person) — Chief Executive Officer
- Manatt, Phelps & Phillips LLP (company) — Legal Counsel
FAQ
What is the primary purpose of this S-1/A filing?
This S-1/A filing is an amendment to the initial registration statement for NeOnc Technologies Holdings, Inc.'s proposed initial public offering.
When was this amendment filed with the SEC?
The amendment was filed with the Securities and Exchange Commission on January 30, 2025.
Who is the Chief Executive Officer of NeOnc Technologies Holdings, Inc.?
Dr. Thomas C. Chen is the Chief Executive Officer of NeOnc Technologies Holdings, Inc.
What is the business address of NeOnc Technologies Holdings, Inc.?
The business address is 2 Dole Drive, Westlake Village, CA 91362.
What is the Standard Industrial Classification (SIC) code for NeOnc Technologies Holdings, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,548 words · 18 min read · ~15 pages · Grade level 14.6 · Accepted 2025-01-31 06:21:46
Key Financial Figures
- $13,117,000 — we raised an aggregate of approximately $13,117,000 in gross proceeds from the sales of our
- $1.25 — les of our stock at an average price of $1.25 per share. In June and July 2024, we is
- $13,750,439 — ersion of an aggregate of approximately $13,750,439 of indebtedness at a price of $12.00 pe
- $12.00 — 3,750,439 of indebtedness at a price of $12.00 per share. Between June and October 202
- $4,616,000 — are for gross proceeds of approximately $4,616,000. We have also engaged RBW Capital Part
- $16.00 — es in a private placement at a price of $16.00 per share, such issuance to occur prior
- $10,000,000 — are for gross proceeds of approximately $10,000,000. All 624,999 shares of common stock are
- $153,462 — 31, 2024 have only generated revenue of $153,462. We do not anticipate generating signif
- $9,645,482 — foreseeable future. We had net loss of $9,645,482, $14,921,065 and $3,046,757 for the nin
- $14,921,065 — future. We had net loss of $9,645,482, $14,921,065 and $3,046,757 for the nine months ende
- $3,046,757 — net loss of $9,645,482, $14,921,065 and $3,046,757 for the nine months ended September 30,
- $48,355,463 — 2024, we had an accumulated deficit of $48,355,463. Market Opportunity The World Health
- $166.5 billion — et is estimated to grow at 9.4% CAGR to $166.5 billion by 2028 and the global brain tumor drug
- $4.4 billion — drug market to grow at CAGR of 9.0% to $4.4 billion by 2029. iHeathcareAnalys has reporte
- $2.3 billion — et is expected to grow at 12.7% CAGR to $2.3 billion by 2029. According to the book, Gliobla
Filing Documents
- neonctechnologies_s1a.htm (S-1/A) — 3154KB
- neonctechnologies_ex5-1.htm (EX-5.1) — 12KB
- neonctechnologies_ex10-40.htm (EX-10.40) — 83KB
- neonctechnologies_ex10-41.htm (EX-10.41) — 95KB
- neonctechnologies_ex10-42.htm (EX-10.42) — 8KB
- neonctechnologies_ex10-43.htm (EX-10.43) — 9KB
- neonctechnologies_ex10-44.htm (EX-10.44) — 8KB
- neonctechnologies_ex10-45.htm (EX-10.45) — 6KB
- neonctechnologies_ex10-46.htm (EX-10.46) — 6KB
- neonctechnologies_ex23-2.htm (EX-23.2) — 4KB
- neonctechnologies_ex107.htm (EX-FILING FEES) — 27KB
- img_001.jpg (GRAPHIC) — 193KB
- img_002.jpg (GRAPHIC) — 266KB
- img_003.jpg (GRAPHIC) — 175KB
- img_004.jpg (GRAPHIC) — 254KB
- img_005.jpg (GRAPHIC) — 248KB
- img_006.jpg (GRAPHIC) — 259KB
- img_007.jpg (GRAPHIC) — 36KB
- img_008.jpg (GRAPHIC) — 114KB
- img_009.jpg (GRAPHIC) — 143KB
- img_010.jpg (GRAPHIC) — 111KB
- img_011.jpg (GRAPHIC) — 41KB
- img_012.jpg (GRAPHIC) — 24KB
- img_013.jpg (GRAPHIC) — 98KB
- img_014.jpg (GRAPHIC) — 86KB
- img_015.jpg (GRAPHIC) — 158KB
- img_016.jpg (GRAPHIC) — 213KB
- img_017.jpg (GRAPHIC) — 175KB
- img_018.jpg (GRAPHIC) — 179KB
- img_019.jpg (GRAPHIC) — 167KB
- img_020.jpg (GRAPHIC) — 132KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- ex10-40_001.jpg (GRAPHIC) — 5KB
- ex10-40_002.jpg (GRAPHIC) — 5KB
- ex10-41_001.jpg (GRAPHIC) — 5KB
- ex10-41_002.jpg (GRAPHIC) — 5KB
- 0001829126-25-000575.txt ( ) — 7678KB
RISK FACTORS
RISK FACTORS 11 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 76 MARKET AND INDUSTRY DATA 78 TRADEMARKS, SERVICE MARKS AND TRADENAMES 79
USE OF PROCEEDS
USE OF PROCEEDS 80 DIVIDEND POLICY 81 CAPITALIZATION 82 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 83
BUSINESS
BUSINESS 106 MANAGEMENT 155 EXECUTIVE AND DIRECTOR COMPENSATION 162 PRINCIPAL AND REGISTERED STOCKHOLDERS 166 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 186
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 191 SHARES ELIGIBLE FOR FUTURE SALE 195 SALE PRICE HISTORY OF OUR CAPITAL STOCK 197 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 198 PLAN OF DISTRIBUTION 202 LEGAL MATTERS 205 EXPERTS 205 WHERE YOU CAN FIND ADDITIONAL INFORMATION 205 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor any of the Registered Stockholders have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor any of the Registered Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Registered Stockholders are offering to sell, and seeking offers to buy, shares of their common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor any of the Registered Stockholders have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by the Registere